Charlie Bengtson, M.D.

Professional Background

Dr. Bengtson is an Assistant Professor of Medicine in the Division of Pulmonary Critical Care and Sleep Medicine. He completed his medical degree at the University of Kansas School of Medicine. He then completed his residency in Internal Medicine and fellowship in Pulmonary and Critical Care Medicine at the University of Kansas Medical Center.

Dr. Bengtson's clinical interests includes caring for those with cystic fibrosis (CF) and lung transplant recipients. He is a member of the adult CF center care team at the University of Kansas Hospital.

• BS, Biochemistry, University of Kansas , Lawrence, KS
• MD, Medicine, University of Kansas School of Medicine, Kansas City, KS
• MSC, Clinical Research, University of Kansas School of Medicine, Kansas City, KS
• Residency, Internal Medicine, University of Kansas School of Medicine, Kansas City, KS
• Clinical Fellowship, Pulmonary and Critical Care Medicine, University of Kansas School of Medicine, Kansas City, KS

• Critical Care Medicine, American Board of Internal Medicine
• Internal Medicine, American Board of Internal Medicine
• Medical license, Kansas Board of Healing Arts
• Pulmonary Disease, American Board of Internal Medicine

• University of Kansas Health System, COVID-19 Therapeutics Committee, Member, 2020 - Present

---

Research

Overview

Dr. Bengtson is involved in clinical and translational research studies aimed at improving outcomes for those affected by cystic fibrosis. He is a member of the CF clinical research team conducting sponsored studies as part of the CF Therapeutics Development Network as well as investigator initiated studies. His research is sponsored by the Cystic Fibrosis Foundation and the National Center for Advancing Translational Sciences

• Targeting inflammation to improve rescue of CFTR by modulator therapy, NIH-NHLBI, PI
• CF READY LTx 2, NIH-NINR, Site-PI
• STRIVE, NIAID, Site-PI

• Kim, Michael, Bengtson, Charles , Yoshida, Makoto, Niloy, Asef, Dennis, John, Baumlin, Nathalie , Salathe, Matthias . 2022. Losartan ameliorates TGF-beta1-induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies. Journal of Clinical investigation, 132 (11)
• Bengtson, Charles, Silswal, Neerupma, Baumlin, Nathalie, Yoshida, Makoto, Dennis, John, Yerrathota, Sireesha, Kim, Michael, Salathe, Matthias. 2022. The CFTR Amplifier Nesolicaftor Rescues TGF-β1 Inhibition of Modulator-Corrected F508del CFTR Function. International Journal of Molecular Sciences, 23 (18), 10956. https://doi.org/10.3390/ijms231810956
• Bengtson, Charles., D, He, Jianghua, Kim, Michael , Salathe, Matthias. 2021. Cystic fibrosis-related diabetes is associated with worse lung function despite ivacaftor use. American Journal of Respiratory and Critical Care Medicine, 204 (11)
• Bengtson, C.., D., Kim, M.., D., Anabtawi, A., He, J., Dennis, J.., S., Miller, S., Yoshida, M., Baumlin, N., Salathe, M.. 2021. Hyperglycaemia in cystic fibrosis adversely affects BK channel function critical for mucus clearance. Eur Respir J, 57 (1). https://www.ncbi.nlm.nih.gov/pubmed/32732330
• Bengtson, Charles., D, Montgomery, Robert., N, Nazir, Usman, Satterwhite, Lewis, Kim, Michael., D, Bahr, Nathan., C, Castro, Mario, Baumlin, Nathalie, Salathe, Matthias . 2021. An open label trial to assess safety of losartan for treating worsening respiratory illness in COVID-19. Frontiers in Intensive Care and Anesthesiology
• Latham, H.., E., Bengtson, C.., D., Satterwhite, L., Stites, M., Subramaniam, D.., P., Chen, G.., J., Simpson, S.., Q.. 2017. Stroke volume guided resuscitation in severe sepsis and septic shock improves outcomes. J Crit Care, 42, 42-46. https://www.ncbi.nlm.nih.gov/pubmed/28672146